Table 1.
Baseline patient demographics and clinical characteristics.
Fig 1.
Gating strategy to identify dendritic cell subpopulations from PBMCs.
For DC phenotyping, B-cell negative (CD19-), Live positive, and Lineage negative (CD3-CD56-) populations were selected. From the CD19-Live+CD3-CD56- parent population, monocytes were identified by CD14+ expression. From the non-monocyte (CD14-) parent gate, myeloid DCs (mDC) were defined by expression of HLADR+CD11c+. From the mDC parent gate, OX40L and TNFa were identified. From the CD14-HLADR+CD11c- parent gate, plasmacytoid DCs (pDCs) were defined by the expression of HLADR+CD123+.
Fig 2.
Gating strategy to identify OX40L and TNFa expression on myeloid dendritic cell (mDC) following stimulation with media, lipopolysaccharide (LPS), or crude peanut extract (CPE).
(a) Baseline healthy control non-peanut allergic, (b) responder of peanut oral immunotherapy, and (c) non-responder of peanut oral immune therapy. Percentages of each population are based on the parent gate (CD14-HLADR+CD11c+ mDCs).
Fig 3.
Mean percent frequency (95% CI) of TNFa-producing myeloid dendritic cells (mDCs) following LPS stimulation in POIT responders and non-responders in the first 24-weeks.
Fig 4.
Mean percent frequency (95% CI) of TNFa-producing myeloid dendritic cells (mDCs) following CPE stimulation in POIT responders and non-responders in the first 24-weeks.
Fig 5.
Mean percent frequency (95% CI) of OX40L myeloid dendritic cells (mDCs) following LPS stimulation in the 1st 24-weeks in POIT responders and non-responders.
Fig 6.
Mean percent frequency (95% CI) of OX40L myeloid dendritic cells (mDCs) following CPE stimulation in the 1st 24-weeks in POIT responders and non-responders.